Featured Research

from universities, journals, and other organizations

Personalizing treatment in idiopathic pulmonary fibrosis

Date:
December 18, 2013
Source:
UCD Conway Institute of Biomolecular & Biomedical Research
Summary:
Researchers have identified a potential biomarker of rapidly progressive pulmonary fibrosis and pinpointed a defective molecular function as a potential therapeutic target.

Masson-trichrome staining of lung sections from TLR3-/- mice shows increased collagen deposition.
Credit: UCD Conway Institute of Biomolecular & Biomedical Research

Researchers in UCD Conway Institute have identified a potential biomarker of rapidly progressive pulmonary fibrosis and pinpointed a defective molecular function as a potential therapeutic target.

Planning treatment for patients with idiopathic pulmonary fibrosis (IPF) is difficult due to the unpredictable course the disease can take. Almost 15% of IPF patients die within 12 months of the initial diagnosis.

However, researchers led by Conway Fellow, Professor Seamas Donnelly of UCD School of Medicine & Medical Science and the Education & Research Centre, St Vincent's University Hospital have identified a potential biomarker of rapidly progressive disease and pinpointed a defective molecular function as a potential therapeutic target.

Idiopathic pulmonary fibrosis (IPF) is a fatal progressive interstitial pneumonia. This chronic inflammatory disease leads to the breakdown of normal lung architecture and the loss of lung function as a result.

In humans, the innate immune system is responsible for recognizing tissue injury and infection. Toll-like receptor 3 (TLR3) is an innate immune system receptor involved in this process of identifying pathogens and defending against them.

Professor Donnelly and his team investigated whether a particular genetic defect in the TLR3 gene might disrupt the normal inflammatory response in IPF and accelerate the progression of the disease.

This specific genetic variation in one of component DNA building blocks of the TLR3 gene is named L412F single-nucleotide polymorphism (SNP).

The UCD research team in collaboration with colleagues in Ireland, the UK and in the USA examined the impact of defective TLR3 function in the lung and on the progression of IPF using lung fibroblasts from patients with and without TLR3 L412F single-nucleotide polymorphism (SNP) and in a laboratory model of the disease.

Commenting on the results, Dr Gordon Cooke, senior postdoctoral research fellow and one of the authors of the recently published article said, "This study identifies the TLR3 L412F polymorphism as a potential marker of rapidly progressive disease and defective TLR3 function represents a potential therapeutic target in IPF."

Professor Seamas Donnelly said, "Our findings suggest a strong mechanistic link between this candidate polymorphism and altered fibrosis, the immune response, and survival in patients. This opens the possibility of focused therapies aimed at restoring TLR3 function as well as supporting an approach to personalizing therapy in IPF by identifying at an early stage those patients at significant risk and tailoring their treatment accordingly."


Story Source:

The above story is based on materials provided by UCD Conway Institute of Biomolecular & Biomedical Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Dwyer DN, Armstrong ME, Cooke G, Keane MP, Donnelly SC, et al. The Toll-like Receptor 3 L412F Polymorphism and Disease Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory & Critical Care Medicine, December 2013

Cite This Page:

UCD Conway Institute of Biomolecular & Biomedical Research. "Personalizing treatment in idiopathic pulmonary fibrosis." ScienceDaily. ScienceDaily, 18 December 2013. <www.sciencedaily.com/releases/2013/12/131218112832.htm>.
UCD Conway Institute of Biomolecular & Biomedical Research. (2013, December 18). Personalizing treatment in idiopathic pulmonary fibrosis. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2013/12/131218112832.htm
UCD Conway Institute of Biomolecular & Biomedical Research. "Personalizing treatment in idiopathic pulmonary fibrosis." ScienceDaily. www.sciencedaily.com/releases/2013/12/131218112832.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com
Ebola Outbreak Poses Little Threat To U.S.: CDC

Ebola Outbreak Poses Little Threat To U.S.: CDC

Newsy (July 29, 2014) The Ebola outbreak in West Africa poses little threat to Americans, according to officials with the Centers for Disease Control and Prevention. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins